TROP-2–Directed ADC Could Be New Standard for Some NSCLCs
In the phase III Opti-TROP-Lung06 trial, patients with newly diagnosed PD-L1-negative, advanced nonsquamous non-small cell lung cancer without targetable alterations who received the TROP-2-directed antibody-drug conjugate sacituzumab tirumotecan and the PD-1 inhibitor pembrolizumab experienced a median progression-free survival (PFS) of 15 months. In comparison, those patients who received standard chemotherapy plus pembrolizumab experienced a median PFS of 5.7 months.
Publication Details
- Journal
- Cancer Discovery
- Published
- 2026-11-14
- DOI
- https://doi.org/10.1158/2159-8290.cd-nw2026-0107
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 0.00